Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in
triple‐negative
,
early‐stage
breast cancer (
NeoCART
): Results from a multicenter, randomized controlled,
open‐label
phase
II
trial
International Journal of Cancer（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要